A Phase 1 interventional study of Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg and Dapagliflozin 10 mg in Diabetes Mellitus, sponsored by Boryung Pharmaceutical Co., Ltd. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-24.
Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing dapagliflozin in Diabetes Mellitus — 8 open to participants now, 10 under way, 4 of them phase 3. dapagliflozin · Diabetes Mellitus.
Among the 51 studies testing dapagliflozin in Diabetes Mellitus, this one is the 37th largest by planned enrollment, is one of 2 that started in 2025, is one of 7 in phase 1, and was the 49th registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →8 of the 51 studies testing dapagliflozin in Diabetes Mellitus are open now, in 7 countries. Recruiting first, the newest first:
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
University of Colorado, Denver · Sites in United States
Ages 18–80
Kun Hua · Sites in China
Ages 18+
The George Institute · Sites in Australia, Sri Lanka
Ages 18+
University of Oklahoma · Sites in United States
Ages 18–85
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 19 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 4 · Phase 3 18 · Phase 4 22
First in 2007; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 52 is below the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 80 across the 51 interventional studies. Of the 35 that completed or were terminated, 15 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 51 have an industry lead sponsor. The 10 most frequent:
Boryung Pharmaceutical Co., Ltd is the lead sponsor of 143 studies on the registry; 23 are open to participants now.
Boryung Pharmaceutical Co., Ltd has 6 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
2 of the studies testing dapagliflozin in Diabetes Mellitus that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT07891234Sherihan AboElyazed Mohamed KhalilEffect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance | 2027-10-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 51 studies testing dapagliflozin in Diabetes Mellitus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was an open-label, randomized, fasting, single-dose, 2-sequence, 2-period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A", "BR3006B," and "BR3006C" in healthy adult volunteers.
A total of 52 healthy volunteers will be enrolled to evaluate the pharmacokinetics and safety profiles of the study drug (one combination tablet of dapagliflozin 10 mg/pioglitazone 30 mg/metformin HCl 1000 mg) and the comparator (co-administration of dapagliflozin 10 mg, pioglitazone 30 mg, and metformin HCl 1000 mg, one tablet each, respectively) while fasting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
R1+R2+R3: BR3006A, BR3006B, and BR3006C; T: BR3006
Drug: Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg · Drug: Dapagliflozin 10 mg · Drug: Pioglitazone 30 mg · Drug: Metformin HCl 1000 mg
T: BR3006; R1+R2+R3: BR3006A, BR3006B, and BR3006C
Drug: Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg · Drug: Dapagliflozin 10 mg · Drug: Pioglitazone 30 mg · Drug: Metformin HCl 1000 mg
Drug page: Dapagliflozin
Orally administered once per day
Also known as: BR3006
Orally administered once per day
Also known as: BR3006A
Orally administered once per day
Also known as: BR3006B
Orally administered once per day
Also known as: BR3006C
Pharmacokinetic variable - Cmax
Maximum plasma concentration of "BR3006" and "BR3006A," "BR3006B," and "BR3006C"
Time frame: From Day 1, 0 hour (pre-dose) to Day 5 after dose administration
Pharmacokinetic variable - AUCt
Area under the drug concentration-time curve over the time interval of "BR3006" and "BR3006A," "BR3006B," and "BR3006C"
Time frame: From Day 1, 0 hour (pre-dose) to Day 5 after dose administration
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Jul 2026, 12 months after the start.
Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 12 months is above that.
Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dapagliflozin · Pioglitazone · Metformin
Boryung Pharmaceutical Co., Ltd →